Chugai’s TALENTACE Study Shows Tecentriq/Avastin Combo With TACE Improves PFS In Unresectable Liver Cancer

Chugai Pharmaceutical Co., Ltd. announced that the Phase III TALENTACE study evaluating Tecentriq® (atezolizumab) and Avastin® (bevacizumab) in combination with on-demand transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (HCC) met its primary endpoint of TACE-progression-free survival (TACE PFS). The study enrolled patients who had not received prior systemic treatment, and results demonstrated statistically significant and clinically meaningful improvements in TACE PFS.

Although overall survival (OS) data remain immature at the time of the first interim analysis, the study also showed clinically meaningful progression-free survival (PFS) by RECIST v1.1, further supporting the regimen’s efficacy. The TALENTACE study was conducted in China and Japan to evaluate the potential of combining cancer immunotherapy and targeted therapy with TACE in improving outcomes for patients with unresectable HCC.

This is the first Phase III study in Asia to demonstrate a TACE PFS benefit from combining immunotherapy and targeted therapy with TACE in this patient population.